Regimens used in LOT1 according to receipt of ASCT and type of institution
| Regimen and treatment phase . | Public (N = 326∗) . | Private (N = 675∗) . |
|---|---|---|
| Patients who underwent ASCT | n = 98 | n = 325 |
| Induction† | ||
| Anti-CD38–based regimens | 1 (0.8%) | 19 (5.3%) |
| IMID-based regimens | 61 (46.6%) | 5 (1.4%) |
| PI-based regimens | 40 (30.5%) | 197 (55.5%) |
| PI + IMID-based regimens | 23 (17.6%) | 132 (37.2%) |
| Other | 6 (4.6%) | 2 (0.6%) |
| Consolidation†,‡ | ||
| Anti-CD38–based regimens | 1 (5.0%) | 12 (11.4%) |
| IMID-based regimens | 6 (30.0%) | 4 (3.8%) |
| PI-based regimens | 6 (30.0%) | 29 (27.6%) |
| PI + IMID-based regimens | 6 (30.0%) | 60 (57.1%) |
| Other | 1 (5.0%) | 0 (0%) |
| Maintenance†,‡ | ||
| Anti-CD38–based regimens | 0 (0%) | 0 (0%) |
| IMID-based regimens | 45 (69.2%) | 206 (83.4%) |
| PI-based regimens | 19 (29.2%) | 25 (10.1%) |
| PI + IMID-based regimens | 0 (0%) | 11 (4.5%) |
| Other | 1 (1.5%) | 5 (2.0%) |
| Patients who did not undergo ASCT | n = 227 | n = 348 |
| Anti-CD38–based regimens | 1 (0.4%) | 30 (8.0%) |
| IMID-based regimens | 122 (45.2%) | 40 (10.7%) |
| PI-based regimens | 94 (34.8%) | 204 (50.5%) |
| PI + IMID-based regimens | 25 (9.3%) | 78 (20.9%) |
| Other | 28 (10.4%) | 22 (5.9%) |
| Regimen and treatment phase . | Public (N = 326∗) . | Private (N = 675∗) . |
|---|---|---|
| Patients who underwent ASCT | n = 98 | n = 325 |
| Induction† | ||
| Anti-CD38–based regimens | 1 (0.8%) | 19 (5.3%) |
| IMID-based regimens | 61 (46.6%) | 5 (1.4%) |
| PI-based regimens | 40 (30.5%) | 197 (55.5%) |
| PI + IMID-based regimens | 23 (17.6%) | 132 (37.2%) |
| Other | 6 (4.6%) | 2 (0.6%) |
| Consolidation†,‡ | ||
| Anti-CD38–based regimens | 1 (5.0%) | 12 (11.4%) |
| IMID-based regimens | 6 (30.0%) | 4 (3.8%) |
| PI-based regimens | 6 (30.0%) | 29 (27.6%) |
| PI + IMID-based regimens | 6 (30.0%) | 60 (57.1%) |
| Other | 1 (5.0%) | 0 (0%) |
| Maintenance†,‡ | ||
| Anti-CD38–based regimens | 0 (0%) | 0 (0%) |
| IMID-based regimens | 45 (69.2%) | 206 (83.4%) |
| PI-based regimens | 19 (29.2%) | 25 (10.1%) |
| PI + IMID-based regimens | 0 (0%) | 11 (4.5%) |
| Other | 1 (1.5%) | 5 (2.0%) |
| Patients who did not undergo ASCT | n = 227 | n = 348 |
| Anti-CD38–based regimens | 1 (0.4%) | 30 (8.0%) |
| IMID-based regimens | 122 (45.2%) | 40 (10.7%) |
| PI-based regimens | 94 (34.8%) | 204 (50.5%) |
| PI + IMID-based regimens | 25 (9.3%) | 78 (20.9%) |
| Other | 28 (10.4%) | 22 (5.9%) |
IMID, immunomodulatory drug; PI, proteasome inhibitor.
A total of 20 of 1021 patients who could be classified according to funding source had missing information.
More than 1 regimen may have been used within LOT1. As a result, the total number of treatments across treatment categories may be larger than the number of patients.
Not all patients who underwent ASCT received consolidation or maintenance therapy.